Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Plenary Session:  The 2016 National Landscape, 2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

covers in REAL TIME

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

 In Attendance, steaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://www.massbio.org/events/2016-massbio-annual-meeting-1120

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA

http://pharmaceuticalintelligence.com/2016/03/02/2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-cambridge-ma/

Plenary Session:  The 2016 National Landscape

• Jeanne Blake, Medical Television Journalist/News Anchor, Author, and Founder of Blake Works (Moderator)

1. Value-based Pricing – complicated matrix
2. Cost effectiveness as driving pricing
3. Obama requested $17Million for Cancer drug development
4. Challenges for Big DAta to advance moonshot initiative

• Amir Nashat, Managing Partner, Polaris

1. R&D expense goes up MassBio do not approve negative effects on R&D
2. Inventing medicine is very difficult
3. Insurance companies increase premium
4. Work of FDA is very important as approvals, directions, inspirations, innovative drugs not me, too drugs – not celebrated enough
5. Productivity in Biotech is very high
6. Big Data – Business Policies will use big data more than in the past – more accessible
7. Who owns the Data?

• Paris Panayiotopoulos, CEO, ARIAD

1. Innovations  continues in Biotech since mid 80s.
2. prolongation of life to be a public good, it will benefit society as a whole

• Daniel Durham, Exec VP, Health Policy, Biotechnology Innovation Organization (BIO)

1. Value of Products
2. Moonshot in Cancer drug development
3. Innovation and Investment
4. Interoperability and system costs – need be shared
5. Mathematician vs Physicians